Iovance Q1 2026 loss of $0.19 on $71.4M revenue in line, affirms Q2 and 2026 revenue guidance
Iovance posts Q1 2026 loss of $0.19 on $71.4M revenue in line, affirms Q2 and 2026 revenue guidance
- Company guides Q2 2026 product revenue to $86–88 million, maintaining previously issued outlook range.
- Company maintains full-year 2026 product revenue guidance of $350–370 million, unchanged from prior expectations.
- Positive initial lifileucel data showed a 40% confirmed objective response rate in metastatic serous endometrial cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.